It seems that aprepitant could be an intelligent bullet against cancer; however, it is surprising and incomprehensible that pharmaceutical companies have had no interest to date in the SP/NK-1R system as a potential strategy for the treatment of cancer when other research lines have been actively developed. Here, TACR1 is linked to cancer.